Jacqulyne Robichaux

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Jacqulyne Robichaux, Yasir Y. Elamin, Zhi Tan et al. · Nature Medicine · 2018 · 455 citations

Medicine, Oncology, Pharmacology +14

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Jacqulyne Robichaux, Xiuning Le, R. S. K. Vijayan et al. · Nature · 2021 · 452 citations · Full text

Medicine, Molecular Genetics, Oncology +14

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i> -Mutant NSCLC

Xiuning Le, Sonam Puri, Marcelo V. Negrão et al. · Clinical Cancer Research · 2018 · 386 citations

Medicine, Oncology, Pharmacology +17

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Marcelo V. Negrão, Ferdinandos Skoulidis, Meagan Montesion et al. · Journal for ImmunoTherapy of Cancer · 2021 · 292 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

Jacqulyne Robichaux, Yasir Y. Elamin, R. S. K. Vijayan et al. · Cancer Cell · 2019 · 241 citations · Full text

Medicine, Oncology, Pharmacology +14